Mendel Capital Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2M Buy
7,949
+10
+0.1% +$2.15K 0.9% 24
2026
Q1
$1.73M Buy
+7,939
New +$1.76M 0.87% 29
2025
Q3
$1.79M Buy
7,746
+115
+2% +$23.4K 0.94% 24
2025
Q2
$1.42M Sell
7,631
-34
-0.4% -$6.32K 0.81% 29
2025
Q1
$1.61M Buy
7,665
+423
+6% +$82.2K 0.97% 22
2024
Q4
$1.29M Buy
7,242
+29
+0.4% +$5.33K 0.78% 30
2024
Q3
$1.42M Buy
7,213
+216
+3% +$40.3K 0.87% 29
2024
Q2
$1.2M Buy
6,997
+71
+1% +$11.8K 0.78% 31
2024
Q1
$1.26M Buy
6,926
+905
+15% +$156K 0.83% 27
2023
Q4
$933K Buy
6,021
+254
+4% +$37K 0.67% 37
2023
Q3
$860K Buy
5,767
+139
+2% +$20.4K 0.71% 35
2023
Q2
$758K Buy
5,628
+81
+1% +$11.9K 0.61% 43
2023
Q1
$884K Buy
5,547
+843
+18% +$129K 0.8% 31
2022
Q4
$760K Buy
4,704
+224
+5% +$34.3K 0.79% 32
2022
Q3
$601K Buy
4,480
+548
+14% +$78.6K 0.71% 33
2022
Q2
$602K Sell
3,932
-191
-5% -$29.2K 0.67% 31
2022
Q1
$668K Buy
4,123
+32
+0.8% +$4.65K 0.63% 32
2021
Q4
$554K Buy
+4,091
New +$483K 0.51% 37

Other funds holding ABBV

Mendel Capital Management's ABBV Position: Q2 2026 in Review

Mendel Capital Management increased its AbbVie (ABBV) stake by 0.13% in Q2 2026, buying an estimated $2.15K and bringing the position to 7,949 shares worth $2M. The position accounts for 0.9% of the portfolio, ranked #24.

Mendel Capital Management first reported a position in ABBV in Q4 2021 and has held it in 18 quarters since. 2,121 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Mendel Capital Management held 7,949 shares of AbbVie worth $2M as of Q2 2026.
  • Mendel Capital Management bought 10 AbbVie shares in Q2 2026, an estimated $2.15K.
  • AbbVie made up 0.9% of Mendel Capital Management's portfolio in Q2 2026, its #24 holding.
  • Mendel Capital Management first reported a position in AbbVie in Q4 2021 and has held it in 18 quarters since.
  • 2,121 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Mendel Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.